Tucker Edmister, Sara
Del Rosario Hernández, Thaís
Ibrahim, Rahma
Brown, Cameron A.
Gore, Sayali V.
Kakodkar, Rohit
Kreiling, Jill A.
Creton, Robbert
Funding for this research was provided by:
National Institutes of Health (P20GM119943, R01GM136906)
Article History
Received: 10 December 2021
Accepted: 1 April 2022
First Online: 21 April 2022
Competing interests
: Brown University submitted a provisional patent application on the treatment of neurodegenerative disease using CsA-type compounds (application 63/193,935, R.C. inventor, S.T.E., R.I., R.K. and J.A.K. contributors). The University hired a company, Wave Strategy, which mediates contacts with strategic partners, investors and industry experts to accelerate the introduction of CsA-type drugs to the market. The authors declare that they do not have other competing interests.